Skip to main content
. Author manuscript; available in PMC: 2020 Apr 1.
Published in final edited form as: Endocr Relat Cancer. 2019 Jan 1;26(4):425–436. doi: 10.1530/ERC-19-0011

Figure 2. Palbociclib activity in ATC cell lines.

Figure 2.

A, calculated EC50 for the human and mouse ATC cell lines analyzed. B, correlation between mRNA expression of CDK4 and sensitivity to palbociclib in human ATC cell lines. C, cell cycle distribution of two human ATC cell lines after 72 hours treatment with 120nM (EC75) palbociclib. D, apoptotic profile of THJ16T cell treated for 72 and 96 hours with 120nM (EC75) palbociclib. PI: propidium iodide; AV: annexin V.